Optimizing the management of metastatic colorectal cancer
Critical Reviews in Oncology/Hematology, ISSN: 1040-8428, Vol: 75, Issue: 1, Page: 15-26
2010
- 4Citations
- 19Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations4
- Citation Indexes4
- CrossRef3
- Captures19
- Readers19
- 19
Review Description
The prognosis of patients with metastatic colorectal cancer has significantly improved in the last few years, with the introduction into the clinical practice of new cytotoxic treatments, the availability of non-cross resistant agents after the front-line treatment failure, and the combination of targeted agents (i.e., the inhibitors of the epidermal growth factor and vascular endothelial growth factor pathways) with conventional drugs. All these options must be incorporated into a complex strategy of management, in which a customized management according to the disease status, with an intensified induction approach followed by maintenance (and reinduction), should be investigated.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S104084280900198X; http://dx.doi.org/10.1016/j.critrevonc.2009.09.008; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77953807967&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/19837601; https://linkinghub.elsevier.com/retrieve/pii/S104084280900198X; https://dx.doi.org/10.1016/j.critrevonc.2009.09.008
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know